The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after a safety concern was found to be unrelated ...
Novavax (NASDAQ:NVAX) shares climbed 12% premarket on Monday after the U.S. FDA lifted clinical hold on the investigational new drug application for the pharma firm’s COVID-19-Influenza ...
Novavax received ... trials for its COVID-19-influenza combination (CIC) and standalone influenza vaccines. The FDA lifted a clinical hold that had been placed on Novavax's investigational new ...
Novavax is already poised to benefit from a separate combined Covid-flu vaccine ... combined shot. Meanwhile, Moderna said last week that it plans to file for FDA approval of its own combo vaccine ...
The lifted hold applies to Novavax’s flu ... combo vaccine. A trial participant who’d received the shot in Jan. 2023 later developed motor neuropathy, or muscle weakness, leading the FDA ...
GAITHERSBURG, Md., Nov. 11, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today ...
Novavax has announced that the US Food and Drug Administration (FDA) has lifted its clinical hold on a late-stage study of the company’s COVID-19/influenza combination and stand-alone influenza ...
(Reuters) -The U.S ... hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after a safety ...
The US Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu ... shot, the company said. "The information provided to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results